Gregory Merlo

Gregory Merlo

Auto-generated profile, based on publicly available information

Gregory Merlo

Clinical Excellence Queensland Queensland Health Brisbane Queensland Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2014 in Applied Health Economics and Health Policy
Verified
Journal Article
Closed access
PDF file
GMGregory Merlo
Gregory Merlo
KPKatie Page
Katie Page
JRJulie Ratcliffe
Julie Ratcliffe
KHKate Halton
Kate Halton
NGNicholas Graves
Nicholas Graves

29 November 2016 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
GMGregory Merlo
Gregory Merlo
NGNicholas Graves
Nicholas Graves
DBDavid Brain
David Brain
LCLuke Connelly
Luke Connelly

9 December 2020 in Health Economics Review
Verified
Journal Article
Open access
PDF file
GMGregory Merlo
Gregory Merlo
MDMieke van Driel
Mieke van Driel
LHLisa Hall
Lisa Hall
Introduction: Discrete choice experiments (DCEs) have been used to measure patient and healthcare professionals preferences in a range of settings internationally. Using DCEs in primary care is valuable for determining how to improve rational shared decision making. The purpose of this systematic review is to assess the validity of the methods used for DCEs assessing the decision making of healthcare professionals in primary care. Main body: A systematic search was conducted to identify articles with original data from a discrete choice experiment where the population was primary healthcare professionals. All publication dates from database inception to 29th February 2020 were included. A data extraction and validity assessment template based on guidelines was used. After screening, 34 studies met the eligibility criteria and were included in the systematic review. The sample sizes of the DCEs ranged from 10 to 3727. The published DCEs often provided insufficient detail about the process of determining the attributes and levels. The majority of the studies did not involve primary care healthcare professionals outside of the research team in attribute identification and selection. Less than 80% of the DCEs were piloted and few papers investigated internal or external validity. Conclusions: For findings to translate into improvements in rational shared decision making in primary care DCEs need to be internally and externally valid and the findings need to be able to be communicated to stakeholders in a way that is understandable and relevant.

15 June 2024 in BioDrugs
Verified
Journal Article
Open access
PDF file
CRChad Rieger
Chad Rieger
JDJudith Ann Dean
Judith Ann Dean
LHLisa Hall
Lisa Hall
PVPaola Vasquez
Paola Vasquez
GMGregory Merlo
Gregory Merlo
Background and Objective Biosimilars represent an opportunity to realise savings against the costs of innovative medicines. Despite efforts made by stakeholders, there are numerous barriers to the uptake of biosimilars. To realise the promise of biosimilars reducing costs, barriers must be identified, understood, and overcome, and enablers magnified. The aim of this systematic review is to summarise the enablers and barriers affecting uptake of biosimilars through the application of a classification system to organise them into healthcare professional (HCP), patient, or systemic categories. Methods A systematic literature search was performed in PubMed, Scopus, CINAHL, eConlit, and Embase. Included were primary research studies published in English between Jan 2017 through June 2023 focused on enablers and barriers affecting uptake of biosimilars. Excluded studies comprised comparisons of biosimilar efficacy and safety versus the reference biologic. One reviewer extracted data that included classification of barriers or enablers, the sub-classification, and the identification of the degree of agency associated with the actor through their role and associations as a mediator within their network, through the application of Actor Network Theory. The data were validated by a second reviewer (PV). Results Of the 94 studies included, 59 were cross-sectional, 20 were qualitative research, 12 were cohort studies, and three were economic evaluations. Within the review, 51 of the studies included HCP populations and 35 included patients. Policies and guidelines were the most cited group of enablers, overall. Systemic enablers were addressed in 29 studies. For patients, the most frequently cited enabler was positive framing of a biosimilar, while for HCPs, cost benefit was the most frequently noted enabler. The most frequently discussed systemic barrier to biosimilar acceptance was lack of effective policies or guidelines, followed by lack of financial incentives, while the most significant barriers for HCPs and patients, respectively, were their lack of general knowledge about biosimilars and concerns about safety and efficacy. Systemic actors and HCPs most frequently acted with broad degree of agency as mediators, while patient most frequently acted with a narrow degree of agency as mediators within their networks. Conclusions Barriers and enablers affecting uptake of biosimilars are interconnected within networks, and can be divided into systemic, HCP, and patient categories. Understanding the agency of actors within networks may allow for more comprehensive and effective approaches. Systemic enablers in the form of policies appear to be the most effective overall levers in affecting uptake of biosimilars, with policy makers advised to give careful consideration to appropriately educating HCPs and positively framing biosimilars for patients.

28 May 2022 in Family Practice
Verified
Journal Article
Open access
PDF file
EBEmma J Baillie
Emma J Baillie
GMGregory Merlo
Gregory Merlo
PMParker Magin
Parker Magin
ATAmanda Tapley
Amanda Tapley
KMKatie J Mulquiney
Katie J Mulquiney
MDMieke L van Driel
Mieke L van Driel
Background: Most antibiotic prescribing for upper respiratory tract infections (URTIs) and acute bronchitis is inappropriate. Substantive and sustained reductions in prescribing are needed to reduce antibiotic resistance. Prescribing habits develop early in clinicians’ careers. Hence, general practice (GP) trainees are an important group to target. Objectives: We aimed to establish temporal trends in antibiotic prescribing for URTIs and acute bronchitis/bronchiolitis by Australian GP trainees (registrars). Methods: A longitudinal analysis, 2010–2019, of the Registrars Clinical Encounters in Training (ReCEnT) dataset. In ReCEnT, registrars record clinical and educational content of 60 consecutive consultations, on 3 occasions, 6 monthly. Analyses were of new diagnoses of URTI and acute bronchitis/bronchiolitis, with the outcome variable a systemic antibiotic being prescribed. The independent variable of interest was year of prescribing (modelled as a continuous variable). Results: 28,372 diagnoses of URTI and 5,289 diagnoses of acute bronchitis/bronchiolitis were recorded by 2,839 registrars. Antibiotic prescribing for URTI decreased from 24% in 2010 to 12% in 2019. Prescribing for acute bronchitis/bronchiolitis decreased from 84% to 72%. “Year” was significantly, negatively associated with antibiotic prescribing for both URTI (odds ratio [OR] 0.90; 95% confidence interval [CI]: 0.88–0.93) and acute bronchitis/bronchiolitis (OR 0.92; 95% CI: 0.88–0.96) on multivariable analysis, with estimates representing the mean annual change. Conclusions: GP registrars’ prescribing for URTI and acute bronchitis/bronchiolitis declined over the 10-year period. Prescribing for acute bronchitis/bronchiolitis, however, remains higher than recommended benchmarks. Continued education and programme-level antibiotic stewardship interventions are required to further reduce registrars’ antibiotic prescribing for acute bronchitis/bronchiolitis to appropriate levels.

24 October 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
EEEmma Eek
Emma Eek
MDMieke van Driel
Mieke van Driel
MFMagnus Falk
Magnus Falk
Samantha HollingworthSamantha Hollingworth
Samantha Hollingworth
GMGregory Merlo
Gregory Merlo